Zacks Investment Research on MSN

NVO down 42% year to date: Is this an indication to sell the stock?

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
C&EN

Looming GLP-1 drug patent expirations draw generics firms

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Industry experts ...